Among all patients treated with PEG-IFN + RBV, 61% (25/41) were undergoing their first treatment for hepatitis C, and 39% (16/41) were being retreated due to the failure of treatment with conventional IFN. The gene discussed is IFNA1; the disease is hepatitis C virus infection.